RxDoctor Payments Data

Don Allred, DO

Family Medicine · Riverton, UTNPI 1174510044

Payments from drug & device makers

$5,036in general payments, 2019–2025

Across 283 payments — averaging $17.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Lilly USA, LLC$416
  • GSK$408
  • AstraZeneca$335
  • Novo Nordisk$261
  • Merck$218
  • plus $2K from 35 others

What the payments were for

  • Food & beverage$5,036100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,036 in reported general payments places this provider in the 80th percentile of 928 family medicine providers in Utah.

See all family medicine providers in Utah

Medicare billing

Part B allowed, 2024
$92,078
Medicare patients
254
Services billed
4,721

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide56$80,259
EliquisApixaban53$62,427
Soliqua 100-33Insulin Glargine/Lixisenatide36$61,663
FarxigaDapagliflozin Propanediol40$45,225
TrulicityDulaglutide22$29,322
XareltoRivaroxaban27$22,265
MounjaroTirzepatide15$20,683
Humalog Kwikpen U-100Insulin Lispro17$7,244
Omeprazole193$4,501
Rosuvastatin Calcium232$3,223
Arnuity ElliptaFluticasone Furoate11$3,011
Atorvastatin Calcium222$2,825
Levothyroxine Sodium230$2,444
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen49$2,425
Gabapentin67$2,271

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$261$80,25956 claims
PfizerEliquis$210$62,42753 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$178$61,66336 claims
Lilly USA, LLCTrulicity, Mounjaro$416$50,00537 claims
AstraZenecaFarxiga$335$45,22540 claims
Johnson & JohnsonXarelto$156$22,26527 claims
GSKArnuity Ellipta$408$3,01111 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 928 family medicine providers in Utah.

Other family medicine in Riverton

See the full list for Utah

Where these figures come from

Is this you, or does something look wrong? →